caa a22 4500 475833392 CHVBK 20180406123847.0 cr unu---uuuuu 170329e20001201xx s 000 0 eng 10.1023/A:1007802630604 doi (NATIONALLICENCE)springer-10.1023/A:1007802630604 Glucose-Insulin-Potassium Reduces Infarct Size When Administered During Reperfusion [Elektronische Daten] [Anne Jonassen, Ellen Aasum, Rudolph Riemersma, Ole Mjøs, Terje Larsen] Coronary reperfusion improves ventricular function and survival after infarction, but the metabolic conditions at this time may not be optimal to protect the heart. The objective of this study was to evaluate if metabolic support with glucose-insulin-potassium (GIK) administered at the time of coronary reperfusion could elicit the same cardioprotection as GIK infusion during the entire ischemia/reperfusion period. Three groups of anesthetized, open-chest rats were subjected to 30 minutes of regional ischemia and 180 minutes of reperfusion. Groups 1 (controls) and 2 (GIKIR) received saline or GIK, respectively, throughout the whole experimental period, whereas a third group (GIKR) received GIK from the onset of reperfusion only. Infarct size was significantly reduced in the GIK-treated groups, compared with controls (GIKIR 44 ± 5% and GIKR 45 ± 5% vs. control 66 ± 4%; P < 0.05). Postischemic recovery of cardiac function improved when GIK was only administered during the reperfusion phase. Furthermore, infusion of GIK resulted in reduced plasma concentrations of free fatty acids and increased plasma glucose (both P < 0.05) compared with controls. This study demonstrates that glucose-insulin-potassium administration at the onset of the postischemic reperfusion period is as cardioprotective as administration of GIK during the entire ischemia/reperfusion period. Kluwer Academic Publishers, 2000 glucose nationallicence insulin nationallicence myocardial infarction nationallicence fatty acids nationallicence Jonassen Anne Department of Medical Physiology, Institute of Medical Biology, University of Tromsø, Tromsø, Norway aut Aasum Ellen Department of Medical Physiology, Institute of Medical Biology, University of Tromsø, Tromsø, Norway aut Riemersma Rudolph Department of Cardiology and Medicine (RIE), University of Edinburgh, Edinburgh, United Kingdom aut Mjøs Ole Department of Medical Physiology, Institute of Medical Biology, University of Tromsø, Tromsø, Norway aut Larsen Terje Department of Medical Physiology, Institute of Medical Biology, University of Tromsø, Tromsø, Norway aut Cardiovascular Drugs and Therapy Kluwer Academic Publishers 14/6(2000-12-01), 615-623 0920-3206 14:6<615 2000 14 10557 https://doi.org/10.1023/A:1007802630604 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1023/A:1007802630604 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Jonassen Anne Department of Medical Physiology, Institute of Medical Biology, University of Tromsø, Tromsø, Norway aut NATIONALLICENCE 700 1- Aasum Ellen Department of Medical Physiology, Institute of Medical Biology, University of Tromsø, Tromsø, Norway aut NATIONALLICENCE 700 1- Riemersma Rudolph Department of Cardiology and Medicine (RIE), University of Edinburgh, Edinburgh, United Kingdom aut NATIONALLICENCE 700 1- Mjøs Ole Department of Medical Physiology, Institute of Medical Biology, University of Tromsø, Tromsø, Norway aut NATIONALLICENCE 700 1- Larsen Terje Department of Medical Physiology, Institute of Medical Biology, University of Tromsø, Tromsø, Norway aut NATIONALLICENCE 773 0- Cardiovascular Drugs and Therapy Kluwer Academic Publishers 14/6(2000-12-01), 615-623 0920-3206 14:6<615 2000 14 10557 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer